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Lixivaptan: a vasopressin receptor
antagonist for the treatment of
hyponatremia
Mitchell H. Rosner1
Hyponatremia, the most common electrolyte disorder encountered in
clinical practice, is associated with significant morbidity and mortality.
The introduction of medications that specifically antagonize the
vasopressin V2 receptor (vaptans) has provided a safe and effective
means of therapy. Lixivaptan is the newest of these agents that reliably
increase serum sodium levels in patients with euvolemic hyponatremia.
However, significant questions remain regarding the specific indications
for vaptans, and their potential impact on morbidity and mortality
associated with hyponatremia.
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Hyponatremia is the most common
electrolyte disorder encountered in clini-
cal practice, and recent data have demon-
strated that it is associated with an
increase in mortality and morbidity even
in patients in whom overt clinical symp-
toms may not be demonstrable.1–3 Typi-
cally, the evaluation of patients with
hyponatremia relies on assessment of
volume status and classifies patients into
hypovolemic, euvolemic, and hyper-
volemic states. This classification schema
allows for determination of the under-
lying cause as well as aiding the clinician
in making decisions on appropriate
therapy. The most common forms of
hyponatremia encountered in clinical
practice are hypervolemic (due to con-
gestive heart failure or cirrhosis) and
euvolemic (largely due to the syndrome
of inappropriate antidiuretic hormone
action). Traditional therapies for hypo-
natremia have been limited, suboptimal,
unreliable, and potentially toxic (Table 1).
However, in 2005 the first drug that
specifically antagonizes arginine vasopres-
sin action at the receptor level was
approved (the intravenous drug conivap-
tan, which antagonizes both the vaso-
pressin V1a and V2 receptors) (Figure 1).
In 2009, an oral vasopressin V2 receptor
antagonist, tolvaptan, was also approved
for the treatment of euvolemic and
hypervolemic hyponatremia. Both of
these agents (broadly termed ‘vaptans’)
had clinical trial data demonstrating their
efficacy in increasing serum sodium levels
as well as increasing the percentage of
patients with hyponatremia who normali-
zed their serum sodium levels as com-
pared with placebo.4,5 Data also demon-
strate the long-term safety and efficacy
(out to approximately 2 years) of
tolvaptan.6 The ability to specifically
target arginine vasopressin provided a
physiologically based therapy for hypo-
natremia that was safe and reliable.
In two articles in this issue of Kidney
International, Abraham and colleagues
report on the effects of a new oral,
non-peptide vasopressin V2 receptor,
lixivaptan, in the treatment of both in-
and outpatients with euvolemic hypo-
natremia.7,8 The studies, LIBRA and
HARMONY, differ in that the former
trial required initial titration of
lixivaptan in the inpatient setting,
whereas, in the latter trial, lixivaptan was
initiated in the outpatient setting (Table 2
summarizes the key characteristics and
outcomes of both trials). Both studies
are randomized, multinational, double-
blinded placebo-controlled phase 3 trials.
In both studies, the dosage of lixivaptan
was titrated on the basis of daily serum
sodium measurements. In both trials,
patients randomized to lixivaptan showed
greater rises in serum sodium values at
day 7 after initiation of therapy, and were
more likely to normalize their serum
sodium, than those given placebo. Cessa-
tion of lixivaptan in both trials led to
worsening of hyponatremia, suggesting
that chronic therapy may be required in
some patients.
Unique to the HARMONY study
was the avoidance of in-hospital drug
initiation and titration, which is cur-
rently recommended with tolvaptan.
Using an outpatient strategy of starting
patients on the lowest possible dose of
lixivaptan (25mg) with point-of-care
testing of the serum sodium at 8 hours
post-dose, the investigators demon-
strated that only three patients in the
lixivaptan group (and one in the placebo
group) exceeded the desired sodium
correction rates in the first 24 h; no sub-
jects experienced an increase in serum
sodium greater than 18mmol/l within
either a 48- or a 72-hour period; and
no subjects had symptoms of osmotic
demyelination syndrome. The ability to
initiate therapy for hyponatremia in the
outpatient setting is advantageous but
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requires careful laboratory monitoring
and the ability to obtain rapid outpatient
measurements of serum sodium values
in order to assess for overly rapid
correction of the serum sodium. At this
time, such a strategy cannot be broadly
recommended and requires further study
to ensure safety.
Also unique to both the LIBRA and
HARMONY trials was the inclusion
of patients with symptoms believed to
be attributable to hyponatremia (head-
ache, fatigue, nausea, vomiting, irritabi-
lity, mental slowing and confusion).
However, these symptoms were not well
defined, and unfortunately, there were no
assessments as to whether these symp-
toms improved coincidently with correc-
tion of the hyponatremia. This was a
missed opportunity, as prior trials with
vaptans excluded such patients, and the
indications for vaptan use in clinical
practice are still uncertain. However, in
both trials, in the lixivaptan treatment
groups there were statistically signifi-
cant improvements in the time required
to complete the Trail Making Test part B
(a neuropsychological test of visual
attention and task switching), which
were not seen in the placebo groups and
are presumably attributable to improve-
ment in the serum sodium levels.
However, correlation of the improvement
on this neuropsychological test with
clinically meaningful improvement in
hyponatremia-related symptoms cannot
be assumed.
In both trials, the increases in serum
sodium were modest, and the details
regarding fluid restriction were at the
discretion of the treating physician and
not prescribed by the protocol. Further-
more, in the LIBRA trial there was a
large imbalance in the percentage of
patients who were on fluid restriction
at baseline (65.4% in the placebo versus
37% in the lixivaptan group). This may
suggest that the patients in the lixivap-
tan group had lower baseline urine
osmolalities and tolerated higher daily
water intakes, a factor that could
confound the results of the study. Also
of concern is that 33% of patients in the
LIBRA cohort and 46.3% of patients in
the HARMONY cohort were taking
medications associated with hypona-
tremia. Many of these patients might
have had restoration of normonatremia
with simple cessation of the offen-
ding medication and would not have
required therapy unless the medication
was deemed indispensable.
Where does this leave us? Clearly
vaptan drugs are effective in antagoniz-
ing the hydroosmotic effects of vasopres-
sin and lead to a predictable rise in
serum sodium levels in patients with
euvolemic or hypervolemic hypona-
tremia. Lixivaptan (pending regulatory
approval) now joins tolvaptan and coni-
vaptan in this group of drugs. How-
ever, as others have pointed out, there is
a large knowledge gap regarding key
clinical questions that would inform us
on how best to use these agents.9 Most
importantly, the indications for vaptans
in the treatment of chronic hyponatremia
remain uncertain. For instance: What
symptoms associated with hyponatremia
are indications for therapy? Is there an
absolute level of hyponatremia that
warrants therapy? What are the poten-
tial health-care-system cost savings asso-
ciated with therapy of hyponatremia?
Can treatment of hyponatremia impact
the morbidity and mortality that have
been associated with this laboratory
abnormality? Thus far, clinical trials
have not answered these key questions.
Furthermore, patients with euvolemic
hyponatremia differ greatly from those
with hypervolemic hyponatremia, and
in the hypervolemic group, patients
with heart failure differ from those
with cirrhosis. How do we tailor vaptan
therapy for these groups? As an example,
Table 1 | Available therapies for hyponatremia
Therapy Benefits Drawbacks
Fluid restriction Simple, easily implemented
Minimal cost
Can be useful in patients
with urine osmolality
o400–600 mosmol/kg
Minimally effective and requires
several days to achieve correction
Hard for patients to remain
compliant
Demeclocycline Effective in raising serum
sodium
Slow response
Potentially nephrotoxic
Expensive
Loop diuretics with
or without salt
supplementation
May allow relaxation of fluid
restriction and decreases
urine-concentrating ability
Requires careful titration and
monitoring
Risk for other electrolyte
abnormalities
Urea Effective and inexpensive Palatability
Limited availability
Hypertonic (3%) saline Effective for severe acute
and symptomatic chronic
hyponatremia
Risk of overly rapid correction
Requires careful, intensive
monitoring
Vasopressin receptor
antagonists
Targets excessive arginine
vasopressin
Safe and effective
Predictable rise in sodium values
No risk for concomitant electrolyte
disorders
Expensive
Induces polyuria
Requires close monitoring of
serum sodium at initiation
with inpatient admission
Table 2 | Key characteristics and outcomes of LIBRA and HARMONY
LIBRA7 HARMONY8
Placebo Lixivaptan Placebo Lixivaptan
No. of subjects 52 54 52 154
Mean age (years) 65.2 66.4 62.7 66.6
% on fluid restriction at baseline 65.4 37 11.5 16.9
Dose at initiation None 50mg
(inpatient)
None 25mg
(outpatient)
Mean baseline sodium (mmol/l) 126.1 127.6 131.6 131.5
Increase in sodium at day 7 (mmol/l) 6.7±0.7 4.5±0.8 0.8±0.6 3.2±0.5
% of subjects with normalized sodium
at day 7
23.1 44.4 12.2 39.4
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a recent trial of a vaptan drug in
cirrhotics demonstrated a significant
decrease in the number of paracenteses
when a vaptan was added to usual care.10
How do we think about these potential
additive benefits of these drugs?
Clearly, the field of hyponatremia
has advanced with the introduction of
safe, effective drugs that antagonize the
hydroosmotic effects of vasopressin.
The two trials presented in this issue7,8
add to the demonstrated benefits of
vaptans to reliably increase serum
sodium values. In recent years, the
field has also seen a greater understand-
ing of the association of hyponatremia
with poor outcomes. However, pros-
pective clinical trials need to go to the
next step by investigating the appro-
priate indications for these drugs. Such
trials would be the next logical step
toward allowing clinicians to effectively
treat hyponatremia and impact the
morbidity and mortality associated
with this common electrolyte disorder.
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Figure 1 |Mechanism of action for vasopressin and V2-receptor antagonists. The binding
of arginine vasopressin to the vasopressin V2 receptor (V2R) stimulates a Gs-coupled
protein that activates adenylyl cyclase, in turn causing production of cyclic adenosine
monophosphate to activate protein kinase A. This pathway increases the exocytosis of vesicles
containing aquaporin water channels and inhibits endocytosis of the vesicles, both of which
result in increases in aquaporin-2 channel formation and apical membrane insertion. This
allows an increase in the permeability of water from the collecting duct. Vasopressin V2
receptors block this effect, and thus the collecting duct remains impermeable to water and
free water excretion increases.
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